SEC Form 4 · accession 0001140361-16-074452
Aptevo Therapeutics Inc. · APVO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Emergent BioSolutions Inc.
10% Owner
Period of report
Jul 29, 2016
Accepted (ET)
Aug 2, 2016 · 5:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001671584
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001 per shareF1 | Jul 29, 2016 | J | 20,229,074 | $0.00 | A | 20,230,074 | D | |
| Common Stock, par value of $0.001 per shareF2 | Aug 1, 2016 | J | 20,230,074 | $0.00 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On July 29, 2016, Aptevo Therapuetics, Inc. ("Aptevo") issued 20,229,074 shares of its common stock to its parent, Emergent Biosolutions Inc ("Emergent"), as partial consideration for Emergent's transfer of its biosciences business to Aptevo.
- F2On August 1, 2016, Emergent made a pro rata distribution of 100% of the outstanding shares of Aptevo common stock to Emergent stockholders of record as of July 22, 2016, the record date for the distribution.